Summary
There is current emphasis for extended integration of pharmacokinetics (PK) and pharmacodynamics (PD) into all phases of new drug development, including large-scale clinical trials. In this paper, we focus on study design and data analysis issues for the investigation of pharmacokinetic/pharmacodynamic and blood level/effect relationships in patients. The application of descriptive and model-based regression statistical methodology for including sparse drug systemic concentration data in the analysis of efficacy and safety is illustrated by examples chosen from diverse therapeutic areas. The population approach, based on mixed-effects modelling, is one such methodology, which also provides new tools for analysis of response vs dose and response vs time data. The existence of a variety of statistical techniques for handling complex PK/PD time-varying data should increase the impact of such data analysis on future drug development.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Balant L.-P., Roseboom H., Gundert-Remy U.M. (1990): Pharmacokinetic criteria for drug research and development. Adv. Drug Res., 19, 1–138.
Salmonson T., Rane A. (1990): Clinical pharmacokinetics in the drug regulatory process. Clin. Pharmacokinet., 18, 177–183.
Sheiner L.B., Stanski D.R., Vozeh S., Miller R.D., Ham J. (1979): Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin. Pharmacol. Ther., 25(3), 358–371.
van Boxtel C.J., Holford N.H.G., Danhof M., eds. (1992): The in vivo study of drug action: Principles and applications of kinetic-dynamic modelling. Amsterdam, Elsevier.
Verotta D., Beal S.L., Sheiner L.B. (1989): Semiparametric approach to pharmacokinetic-pharmacodynamic data. Am. J. Physiol., 256, (Regul. Integ. Comp. Physiol. 25) R1005-R1010.
Verotta D., Sheiner L.B. (1991): Semiparametric analysis of non steady-state pharmacodynamic data. J. Pharmacokinet. Biopharm., 19, 691–712.
Veng-Pedersen P., Mandema J.W., Danhof M. (1991): A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling. J. Pharm. Sci., 80(5), 488–495.
Beal S.L., Sheiner L.B., eds. (1992): NONMEM Users Guides, Version IV. NONMEM Project Group, San Francisco, University of California at San Francisco.
Sheiner L.B., Rosenberg B., Melmon K.L. (1972): Modeling of individual pharmacokinetics for computer-aided drug dosage. Comp. Biomed. Res., 5, 441–459.
Weiner D.L. (1986): NONLIN84/PCNONLIN: Software for the statistical analysis of nonlinear models. Methods Find. Exp. Clin. Pharmacol., 8, 625–628.
Berman M., Beltz W.F., Greif P.C., Chabay R., Boston R.C. (1983): CONSAM user’s guide. National Cancer Institute, NIH, Bethesda, Maryland, USA.
Steiner E.C., Rey T.D., McCroskey D.S. (1990): SimuSolv: Modeling and simulation software. The Dow Chemical Company, Midland, Michigan 48674, USA.
Fuseau E., Sheiner L.B. (1984): Simultaneous modelling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin. Pharmacol. Ther., 35, 733–741.
Kroboth P.D., Smith R.B., Juhl R.P., eds. (1988): Pharmacokinetics and pharmacodynamics: Current problems, potential solutions. Cincinnati, Harvey Whitney Books.
Mallet A. (1986): A maximum likelihood estimation method for random coefficient regression models. Biometrika, 73, 645–656.
Hashimoto Y., Sheiner L.B. (1991): Designs for population pharmacodynamics: Value of pharmacokinetic data and population analysis. J. Pharmacokinet. Biopharm., 19, 333–353.
Sheiner L.B., Beal S.L., Sambol N.C. (1989): Study designs for dose-ranging. Clin. Pharmacol. Ther., 46, 63–77.
Sheiner L.B., Hashimoto Y., Beal S.L. (1991): A simulation study comparing designs for dose ranging. Stat. Med., 10, 303–321.
Rowland M., Sheiner L.B., Steimer J.L., eds. (1985): Variability in Drug Therapy: Description, Estimation and Control. New York, Raven Press.
Temple R. (1983): Discussion paper on the testing of drugs in the elderly. Memorandum of the Food and Drug Administration (September 30), Washington DC, DHHS.
Temple R. (1987): The clinical investigation of drug use by the elderly: Food and Drug guidelines. Clin. Pharmacol. Ther., 42, 681–685.
Koch-Weser J., Klein W. (1971): Procainamide dosage schedules, plasma concentrations and effects. JAMA, 215, 1454–1460.
Kroboth P.D., Schmith V.D., Smith R.B. (1991): Pharmacodynamic modeling: Application to new drug development. Clin. Pharmacokinet., 20, 91–98.
Campbell D.B. (1990): The use of kinetic-dynamic interactions in the evaluation of drugs. Psychopharmacology, 100, 43–450.
Sale M.E., Blaschke T.F. (1992): Ineorporating pharmacokinetic/pharmacodynamic modeling in drug development — Are we ready? Drug Inf. J., 26, 119–124.
Peck C.C. (1992): Population approach in pharmacokinetics and pharmacodynamics: FDA view. In: Rowland M., Asrons L., eds. New strategies in Drug Development and Clinical Evaluation: The population approach. Luxembourg, Commission of the European Communities, pp 157–168.
Peck C.C., Barr W.H., Benet L.Z., et al. (1992): Conference Report: Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin. Pharmacol. Ther., 51, 465–473.
Holford N.H.G., Peck C.C. (1992): Population pharmacodynamics and drug development. In: van Boxtel C.J., Holford N.H.G., Danhof M. eds. The in vivo study of drug action: Principles and applications of kinetic-dynamic modelling. Elsevier, Amsterdam.
Sheiner L.B. (1992): Population approach in drug development: rationale and basic concepts. In: Rowland M., Aarons L. eds. New strategies in Drug Development and Clinical Evaluation: The population approach. Luxembourg, Commission of the European Communities, pp 13–29.
Steimer J.L., Vozeh S., Racine-Poon A., Holford N., O’Neill R. (1993): The population approach: rationale, methods, applications in clinical pharmacology and drug development. In: Welling P.E., Balant L.P., eds. Pharmacokinetics of Drugs. Handbook of Experimental Pharmacology. Heidelberg, Springer-Verlag. (In press)
Danhof M. (1993): Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives. Eur. J. Drug Metab. Pharmacokinet. (this issue).
van Peer A. (1993): Pharmacokinetic-pharmacodynamic relationships in Phase I/Phase II of drug development. Eur. J. Drug Metab. Pharmacokinet. (this issue).
Mandema J.W., Sansom L.N., Dios-Vieitez M.C., Hollander-Jansen M., Danhof M. (1991): Pharmacokinetic-pharmacodynamic modelling of the EEG effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J. Pharmacol. Exp. Ther., 257, 472–478.
Williams R.L. (1992): Dosage Regimen Design: Pharmacodynamic Considerations. J. Clin. Pharmacol. 32, 597–602.
Steimer J.L., Mentre F., Mallet A. (1984): Population studies for evaluation of pharmacokinetic variability: Why? How? When?. In: Aiache J.M., Hirtz J., eds. 2nd European Congress on Biopharmaceutics and Pharmacokinetics, vol. 2: Experimental Pharmacokinetics. Paris, Editions Lavoisier, pp 40–49.
Sheiner L.B., Benet L.Z. (1985): Premarketing observational studies of population pharmacokinetics of new drugs. Clin. Pharmacol. Ther., 38, 481–487.
Hundt H.K.L., Aucamp A.K., Mueller F.O., Potgieter M.A. (1983): Carbamazepine and its major metabolites in plasma: A summary of eight years of therapeutic drug monitoring. Ther. Drug Monit., 5, 427–435.
Mallet A., Mentre F. (1988): An approach to the design of experiments for estimating the distribution of parameters in random models. In: Vichnevetsky R., Borne P., Vignes J., eds. Proc. 12th IMACS World Congress 5, pp 134–137
Food and Drug Administration. (1989): Guideline for the study of drugs likely to be used in the elderly. Centre for Drug Evaluation and Research, Food and Drug Administration. Washington DC, DHHS.
Feutren G., Friend D., Timonen P., Barnes A., Laburte C. (1990): Predictive value of cyclosporin A level for efficacy or renal dysfunction in psoriasis. Br. J. Dermatol., 122, Suppl 36, 85–93.
Eagger S., Levy R. (1992): Serum levels of tacrine in relation to clinical response in Alzheimer’s disease. Int. J. Geriatr. Pay., 7, 115–119.
Antal E.J., Pyne D.A., Starz K.E., Smith R.B. (1988): Probability models in pharmacodynamic analysis of clinical trials. In: Kroboth P.D., Smith R.B., Juhl R.P. eds. Pharmacokinetics and pharmacodynamics: Current problems, potential solutions, vol. 2. Cincinnati, Harvey Whitney Books, pp 220–231.
Cox D.R. (1972): Regression models and life tables (with discussion). J. R. Stat. Soc. B, 34, 187–220.
Yee G.C., Kennedy M.S., Gmur D.J., et al. (1986): Pharmacodynamics of cyclosporine in patients undergoing bone marrow transplantation. Transplant Proc., 18, 774–775.
Yee G.C., Self S.G. (1988): Application of relative risk regression models to pharmacodynamic studies. In: Kroboth P.D., Smith R.B., Juhl R.P. eds. Pharmacokinetics and pharmacodynamics: Current problems, potential solutions, vol. 2. Cincinnati, Harvey Whitney Books, pp 206–218.
Grevel J., Welsh M.S., Kahan B.D. (1989): Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough level monitoring. Ther. Drug Monit., 11, 246–248.
Grevel J., Napoli K.L., Welsh M.S., Atkinson N.E., Kahan B.D. (1991): Prediction of acute graft rejection in renal transplantation: the utility of cyclosporine blood concentrations. Pharmacol. Res., 8(2), 278–281.
Sanathanan L., Peck C. (1991): Pharmacodynamic measures based on CD4 lymphocyte counts for assessing the effect of anti-HIV therapy. In: Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities, pp 207–222.
Ratain M.J., Schilsky R.L., Conley B.A., Egorin M.J. (1990): Pharmacodynamics in cancer therapy. J. Clin. Oncol, 8(10), 1739–1753.
Vozeh S., Uematsu T., Ritz R., Schmidlin O., Kaufman G., Scholer A., Follath F. (1987): Computer-assisted individualized lidocaine dosage: Clinical evaluation and comparison with physician performance. Am. Heart J., 113, 928–933.
Escolano S., Mentre F., Golmard J.L., Diquet B., Mallet A. (1991): A reduced dose of zidovudine in patients with AIDS. N. Engl J. Med., 324, 995.
Mentre F., Mallet A. (1992): Experiences with NPML — Application to dosage individualisation of cyclosporine, gentamicin and zidovudine. In: Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities, pp 75–90.
Escolano S., Mentre F., Golmard J.L., Diquet B., Mallet A. (1991): Plasma concentrations of zidovudine. N. Engl J. Med., 326, 1571.
George S.L. (1988): Use of statistical models in assessing the relationships among pharmacokinetic variables, clinical variables, and outcome. In: Kroboth P.D., Smith R.B., Juhl R.P. eds. Pharmacokinetics and pharmacodynamics: Current problems, potential solutions, vol. 2. Cincinnati, Harvey Whitney Books, pp 186–204.
Laplanche R., Fertil B., Nüesch E., Jais J.P., Niederberger W., Steimer J.L. (1991): Exploratory analysis of population pharmacokinetic data from clinical trials with application to isradipine. Clin. Pharmacol. Ther., 50, 39–54.
Niederberger W., Gonasun L.M., Kutz K., et al. (1987): A population pharmacokinetic study during phase III clinical trials for the calcium antagonist PN 200-110 (isradipine). In: Aiache J.M., Hirtz J., eds. Proc 3rd Eur. Congress Biopharm. Pharmacokinet, Vol. 3, Clinical Pharmacokinetics. Clermont-Ferrand, University of Clermont-Ferrand, pp 45–54.
Chambers J.M., Cleveland W.S., Kleiner B., Tukey P.A. (1983): Graphical methods for data analysis. Wadsworth.
Ebelin M.E., Steimer J.L., Laplanche R., Niederberger W. (1992): An evaluation of population pharmacokinetics during drug development: Experiences with graphical exploratory analysis for isradipine and tropisetron. In: Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities, pp 131–141.
Mandema J.W., Verotta D., Sheiner L.B. (1992): Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokinet. Biopharm., 20, 511–528.
Vozeh S. (1991): Applications of population approach to clinical pharmacokinetics and validation of the results. In: Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities, pp 107–124.
Sanathanan L., Peck C.C., Temple R., Lieberman R., Pledger G. (1991): Randomization, pharmacokinetic-controlled dosing, and titration: an integrated approach for designing clinical trials. Drug Inf. J., 25, 425–431.
Sanathanan L., Peck C.C. (1991): The randomized concentration-controlled trial: an evaluation of its sample size efficiency. Controlled Clin. Trials, 12, 780–794.
Kragh-Sorensen P., Eggert Hansen C., Baastrup P.C., Hvidberg E.F. (1976): Self-inhibiting action of nortriptylin’s anti-depressive effect at high plasma levels. Psychopharmacologia, 45, 305–312.
Vozeh S., Kewitz G., Penuchoud A., Tschan M., Kopp C., Heitz M., Follath F. (1982): Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: The optimal use of intravenously administered aminophylline. Am. Rev. Respir. Dis., 125, 181–184.
Gelenberg A.J., Kane J.M., Keller M.B., et al. (1989): Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N. Engl. J. Med., 321, 1489–1493.
Evans W.E., Crom W.E., Abromowitch M., et al. (1986): Clinical pharmacodynamics of high dose methotrexate in acute lymphocytic leukemia. N. Engl J. Med., 314, 471–477.
Rodman J.H., Abromowitch M., Sinkule J.A., et al. (1987): Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a Phase I trial. J. Clin. Oncol., 7, 1007–1014.
Vozeh S. (1987): Cost-effectiveness of therapeutic drug monitoring. Clin. Pharmacokinet., 13, 131–140.
Rubio A., Cox C., Weintraub M. (1992): Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin. Pharmacokinet., 22(3), 238–246.
Sheiner L.B., Ludden T.M. (1992): Population pharmacokinetics/pharmacodynamics. Annu. Rev. Pharmacol. Toxicol., 32, 185–209.
Aarons L., Mandema J., Danhof M. (1991): A population analysis of the pharmacokinetics and pharmacodynamics of Midazolam in the rat. J. Pharmacokinet. Biopharm., 19, 485–496.
Aarons L. (1993): Sparse data analysis. Eur. J. Drug Metab. Pharmacokinet. (This issue)
Sambol N.C., Sheiner L.B. (1991): Population dose versus response of betaxolol and atenolol: a comparison of potency and variability. Clin. Pharmacol. Ther., 49, 24–31.
Sheiner L.B. (1991): The intellectual health of clinical drug evaluation. Clin. Pharmacol. Ther., 50, 4–9.
Venot A., Mentre F., Herbin M., Siney H., Vinet L., Strauch G. (1992): Nouvelles methodes d’evaluation de la phototoxicite des antibiotiques a partir de l’analyse d’image et d’un modele de population. In: Chastang C., Pons G., Regnier B., eds. Methodes nouvelles en pharmacologie clinique pediatrique. Heidelberg, Springer Verlag
Holford N.H.G. (1992): Parametric models for the time course of drug action: the population approach. In: Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities, pp 193–206.
Schmith V.D., Fiedler-Kelly J., Abou-Donis M., Huffmann C.S., Grasela T.H. (1992): Population pharmacodynamics of doxacurium. Clin. Pharmacol. Ther., 52, 528–536.
Balant L.P. (1993): Blood concentration measurements during clinical trials: potential advantages and some unresolved issues. Appl. Clin. Trials (In press)
Vollmer K.O. et al. (1992): Practical issues in possible implementation of population pharmacokinetics in drug development (discussion). In: Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities, pp 169–179.
O’Neill R.T. (1992): Statistical issues in population models. In: Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities, pp 99–105.
Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities.
Bortey E.B., Gould A.L. (1991): Applying survival methodology to adverse experience occurrences in controlled clinical trials. J. Biopharm. Stat., 1(1), 57–66.
Pollak T. (1990): The exploration of pharmacokinetic and pharmacodynamic data using interactive three-dimensional graphs, a tool borrowed from particle physics. Eur. J. Clin. Pharmacol., 39, 525–532.
Gentleman R., Crowley J. (1991): Graphical Methods for Censored Data. J. Am. Stat. Assoc., 86(415), 678–683.
SAS. (1988): Statistical Analysis System (Version 6). SAS Institute, Inc., Box 8000, Cary, NC 27511
Chambers J.M., Hastie T.J., eds. (1992): Statistical models in S. Wadsworth & Brooks, Pacific Grove, CA
Veng-Pedersen P., Modi N.B. (1992): Neural networks in pharmacodynamic modeling. Is current modeling practice of complex kinetic systems at a dead end? J. Pharmacokinet. Biopharm., 20, 397–412.
Siegel R. (1992): Commentary on ‘Neural networks in pharmacodynamic modeling. Is current modeling practice of complex kinetic systems at a dead end?’ J. Pharmacokinet. Biopharm., 20, 413–416.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steimer, J.L., Ebelin, M.E. & Van Bree, J. Pharmacokinetic and pharmacodynamic data and models in clinical trials. Eur. J. Drug Metab. Pharmacokinet. 18, 61–76 (1993). https://doi.org/10.1007/BF03220009
Issue Date:
DOI: https://doi.org/10.1007/BF03220009